Schedule-dependent cytotoxicity of 5-fluorouracil and Irinotecan in p53 mutant human colon cancer

Journal of Experimental and Clinical Cancer Research

Volumn 26, Issue 2, 2007, Pages 241-251

  Tanaka, K ^a   Inoue, Y ^a   Hiro, J ^a   Yoshiyama, S ^a   Toiyama, Y ^a   Eguchi, T ^a   Miki, C ^a   Kusunoki, Masato ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 fluorouracil; Irinotecan; p53 mutant colon cancer; Schedule dependent cytotoxicity

Indexed keywords

FLUOROURACIL; IRINOTECAN; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CLINICAL ARTICLE; COLON CANCER; COLORIMETRY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG EFFECT; FLOW CYTOMETRY; GENE IDENTIFICATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; UPREGULATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CAMPTOTHECIN; COLONIC NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FLUOROURACIL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LEUCOVORIN; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 34347385001     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Saltz L.B., Cox J.V., Blanke C., Rosen L.S. et al.: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med. 343(13):905-14, 2000.
2. Douillard J.Y., Cunningham D., Roth A.D. et al.: Irinotecan combined with fluorouracil compared to fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multi-centre randomised trial. Lancet 355:1041-1047, 2000.
3. Rothenberg M.L., Meropol N.J., Poplin E.A., Van Cutsem E., Wadler S.: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J. Clin. Oncol. 19:3801-3807, 2001.
4. Ohtsu A., Boku N., Yoshioka T. et al.: A Phase II study of irinotecan in combination with 120-h infusion of 5-fluorouracil in patients with metastatic colorectal carcinoma: Japan Clinical Oncology Group Study (JCOG9703). Jpn J. Clin. Oncol. 33:28-32, 2003.
5. Yalcin S., Oksuzoglu B., Tekuzman G. et al.: Biweekly irinotecan plus bolus 5-fluorouracil and folinic acid in patients with advanced stage colorectal cancer. Jpn J. Clin. Oncol. 33:580-583, 2003.
6. Hwang J.J., Eisenberg S.G., Marshall J.L.: Improving the toxicity of irinotecan/5-FU/leucovorin: a 21-day schedule. Oncology (Huntingt) 17:37-43, 2003.
7. rd, Goldberg RM.: Optimal use of the combination of irinotecan and 5-fluorouracil. Semin. Oncol. 30:68-77, 2003.
8. Saltz L.B., Douillard J.Y., Pirotta N. et al. Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard. Oncologist 6:81-91, 2001.
9. Coutinho A.K., Rocha Lima C.M.: Metastatic colorectal cancer: systemic treatment in the new millennium. Cancer Control. 10:224-238, 2003.
10. Kusunoki M., Yanagi H., Kotera H., Noda M., Yamamura T.: Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression. Int. J. Oncol. 13:653-657, 1998.
11. Kusunoki M., Yanagi H., Noda M., Yamamura T.: The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5FU) in the treatment of unresectable colorectal carcinomas. Oncol. Rep. 6:547-52, 1999.
12. Kusunoki M., Yanagi H., Noda M., Yoshikawa R., Yamamura T.: Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-fluorouracil infusion and oral UFT after resection of hepatic colorectal metastases. Cancer 89:1228-1235, 2000.
13. Yoshikawa R., Kusunoki M., Yanagi H. et al.: Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 61:1029-1037, 2003.
14. Goldwasser F, Shimizu T, Jackman J et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res. 56: 4430-4437, 1996.
15. Mans D.R., Grivicich I., Peters G.J., Schwartsmann G.: Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines. Eur. J. Cancer. 35:1851-1861, 1999.
16. Pavillard V., Formento P., Rostagno P. et al.: Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem. Pharmacol. 56:1315-22, 1998.
17. Cao S., Rustum Y.M.: Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: role of drug sequence and dose. Cancer Res. 60:3717-3721, 2000.
18. Azrak R.G., Cao S., Slocum H.K. et al.: Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin. Cancer Res. 10:1121-9, 2004.
19. Guichard S., Cussac D, Hennebelle I, Bugat R, Canal P. Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo. Int. J. Cancer. 73:729-734, 1997.
20. Guichard S., Hennebelle I., Bugat R., Canal P.: Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem. Pharmacol. 55:667-76, 1998.
21. Hollstein M., Sidransky D., Vogelstein B., Harris C.C.: p53 mutations in human cancers. Science (Washington DC), 253: 49-53, 1991.
22. Levine A., Momand J., Finlay C. A.: The p53 tumor suppressor gene. Nature (Lond.) 351: 453-456, 1991.
23. Toiyama Y., Mizoguchi A., Kimura K. et al.: Persistence of gene expression changes in noninflamed and inflamed colonic mucosa in ulcerative colitis and their presence in colonic carcinoma. World J. Gastroenterol. 11:5151-5155, 2005.
24. Lowe S.W., Bodis S., Mc Clatchey A. et al.: p53 status and the efficacy of cancer therapy in vivo. Science 266:807-810, 1994.
25. Ju J.F., Banerjee D., Lenz H.J. et al.: Restoration of wild-type p53 activity in p53-null HL-60 cells confers multidrug sensitivity. Clin. Cancer Res. 4:1315-1322, 1998.
26. Lenz H.J., Hayashi K., Salonga D. et al.: p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin. Cancer Res. 4(5):1243-1250, 1998.
27. Saltz L.B., Kanowitz J., Kemeny N.E. et al.: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J. Clin. Oncol. 14:2959-2967, 1996.
28. Falcone A., Di Paolo A., Masi G. et al.: Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J. Clin. Oncol. 19:3456-3462, 2001.
29. Nishihara H., Hwang M., Kizaka-Kondoh S., Eckmann L., Insel P.A.:Cyclic AMP promotes cAMP-responsive element-binding protein-dependent induction of cellular inhibitor of apoptosis protein-2 and suppresses apoptosis of colon cancer cells through ERK1/2 and p38 MAPK. J. Biol. Chem. 279:26176-2683, 2004.
30. Ghobrial I.M., Witzig T.E., Adjei A.A.: Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin. 55:178-94, 2005.
31. Wang Q., Wang X., Evers B.M.: Induction of cIAP-2 in human colon cancer cells through PKC delta/NF-kappa B. J. Biol. Chem. 278:51091-51099, 2003.
32. Liu J.J, Nilsson A., Oredsson S., Badmaev V., Zhao W.Z., Duan R.D.: Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis 23:2087-2093, 2002.
33. Kanai F., Marignani P.A., Sarbassova D. et al.: TAZ: a novel transcriptional co-activator regulated by interactions with 14-3-3 and PDZ domain proteins.EMBO J. 19:6778-6791, 2000.
34. Du J., Shi Y., Pan Y. et al.: Regulation of multidrug resistance by ribosomal protein 16 in gastric cancer cells.Cancer Biol Ther. 4:242-247, 2005.
35. Feral C.C., Nishiya N., Fenczik C.A. et al.: CD98hc (SLC3A2) mediates integrin signaling.Proc. Natl Acad. Sci. U S A. 102:355-360, 2005.
36. Ke N., Claassen G., Yu DH et al.: Nuclear hormone receptor NR4A2 is involved in cell transformation and apoptosis.Cancer Res. 64:8208-8212, 2004.
37. Rabizadeh S., Xavier R.J., Ishiguro K. et al: The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J. Biol. Chem. 279:29247-2954, 2004.
38. Crowley-Weber C.L., Payne C.M., Gleason-Guzman M. et al.: Development and molecular characterization of HCT-116 cell lines resistant to the tumor promoter and multiple stress-inducer, deoxycholate. Carcinogenesis 23:2063-2080, 2002.